Mathematical models can assist in broadening use of immuno-oncology drugs to treat autoimmunity
October 31, 2024 The level of immune activation is enormously influential for the progression of…
CertaraOctober 31, 2024
RAPS Sponsored Webcast: Optimizing Pediatric Oncology Drug Development: A Comprehensive Overview
Developing safe and effective oncology medications for children presents unique challenges due to ethical considerations…
CertaraOctober 17, 2024
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
CertaraAugust 19, 2024
Model-Informed Confidence in Oncology Dose Selection
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial…
CertaraAugust 9, 2024
Certara’s MIDD Oncology Capabilities
Improve Oncology Study Decisions with Certara's MIDD Team Transcript: The pace of oncology drug…
CertaraAugust 7, 2024
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology
Bispecific T-cell Engagers (TCEs) are promising anti-cancer treatments that bind to both the CD3 receptors…
CertaraJuly 23, 2024
Accelerating the Progress of Kinase Inhibitors in Oncology
The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…
CertaraMay 20, 2024
